HomeQuestion

How do you sequence HER2-therapy in HER2+ biliary tract cancer with the positive results of tucatinib + trastuzumab and zanidatamab in phase 2 studies?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

What factors would make you choose IPI3/NIVO1 frontline for advanced unresectable and metastatic HCC based on CheckMate 9DW?

When treating with SBRT and immunotherapy for unresectable HCC, how do you sequence the treatment?

In a patient with unresectable HCC who developed immune-related colitis with the first dose of tremelimumab/durvalumab, would you consider continuing durvalumab alone after resolution of the colitis with steroid treatment?

How do you counsel patients on imaging findings after liver SBRT for HCC, particularly with regard to expectations on timing to tumor resolution?

Which neoadjuvant/adjuvant chemotherapy regimen would you select in a patient with resectable stage IB pancreatic head adenocarcinoma and MDS-SF3B1 on luspatercept (baseline Hgb of 8-9 g/dL)?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.